Annex E. International Armaments Strategy
Army Science and Technology Master Plan (ASTMP 1997)


Table E.III-9. Medical Science

MEDICAL SCIENCE UNITED KINGDOM FRANCE GERMANY OTHER COUNTRIES JAPAN PACIFIC RIM FSU
Infectious Diseases a,b,c,d,e
a,b,c,d,e
a,b,c,d,e
a-e Switzerland
b,c,e Sweden
b,c,e Israel
b,c, Italy
b,c,e Netherlands
a,b,c,e
China
b,c
a,b,c
Combat Casualty Care a,b,c
a,b,c
a,b,c
Switzerland
a,b
Sweden
a,b,c
Israel
a,b,c
Italy
a,b,c,
a,b
China
a,b
b,c
Army Operational Medicine a,b,c
a,c
a,b,c
Israel
a,c
Sweden
a,b,c
c
   
Medical Biological Defense a,b,c,d
a,b,c,d
a,b,c,d

Sweden
Switzerland
Netherlands
Israel

a,b,c,d

a,b,c,d
Taiwan
d
d

Infectious Diseases - a: Human genome and Desease Susceptibility; b: non-peptide antivirals; c: rapid diagnosis; d: vaccines; e: delivery of vaccines post exposure
Combat Casualty Care - a: manage acute trauma shock ( blood loss, CNS change and perfusion); b: pharmacology of wound healing and CNS injury repair; c: containment of personnel and equipment after exposure (containment pods and telemedicare)
Army Operational Medicine - a: biomarkers for toxicant exposure (GST, P450, acute phase proteins); b: nutrient additives; c: countermeasure to intense noise
Medical Biological Defense - a; immune response enhancers (interferon, interlukin); b: intracellular transport molecules (M protein); c: block viral docking and replication; d: enhance uptake of drugs to cells (Botox)

Click here to return to ASTMP